Characterization of high-capacity adenovirus production by the quantitative real-time polymerase chain reaction: A comparative study of different titration methods

Journal of Gene Medicine

Volumn 10, Issue 10, 2008, Pages 1092-1101

  Crettaz, Julien ^a   Olague, Cristina ^a   Vales, Africa ^a   Aurrekoetxea, Igor ^a   Berraondo, Pedro ^a   Otano, Itziar ^a   Kochanek, Stephan ^b   Prieto, Jesús ^a   González Aseguinolaza, Gloria ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

High capacity adenovirus; Infection units; Quantitative PCR; Titration

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; HIGH CAPACITY ADENOVIRUS VECTOR; INTERLEUKIN 2; PREALBUMIN; UNCLASSIFIED DRUG; INTERLEUKIN 12; VIRUS DNA;

ACCURACY; ARTICLE; DOT HYBRIDIZATION; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROMOTER REGION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SLOT BLOT HYBRIDIZATION; SPECTROPHOTOMETRY; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS PURIFICATION; VIRUS TITRATION; ADENOVIRUS; ANIMAL; COMPARATIVE STUDY; GENE VECTOR; GENETICS; HELA CELL; HUMAN; METABOLISM; MOUSE; POLYMERASE CHAIN REACTION; STANDARD;

ADENOVIRIDAE; MURINAE;

ADENOVIRIDAE; ANIMALS; DNA, VIRAL; GENETIC VECTORS; GENOME, VIRAL; HELA CELLS; HUMANS; INTERLEUKIN-12; MICE; POLYMERASE CHAIN REACTION;

EID: 58149194203     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1236     Document Type: Article

References (25)

1. Verma IM, Weitzman MD. Gene therapy: 20-first century medicine. Annu Rev Biochem 2005; 74: 711-738.
2. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
3. Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005; 12: S18-27.
4. Zuckerman JB, Robinson CB, McCoy KS, et al. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 1999; 10: 2973-2985.
5. Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cremediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570.
6. Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816-12821.
7. Aurisicchio L, Bujard H, Hillen W, et al. Regulated and prolonged expression of mIFN in immunocompetent mice mediated by a helper dependent adenovirus vector. Gene Ther 2001; 8: 1817-1825.
8. Gu Z, Belzer SW, Gibson CS, et al. Multiplexed, real-time PCR for quantitative detection of human adenovirus. J Clin Microbiol 2003; 41: 4636-4641.
9. Heim A, Ebnet C, Harste G, Pring-Akerblom P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol 2003; 70: 228-239.
10. Puntel M, Curtin JF, Zirger JM, et al. Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Hum Gene Ther 2006; 17: 531-544.
11. Xiong W, Goverdhana S, Sciascia SA, et al. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 2006; 80: 27-37.
12. Kreppel F, Biermann V, Kochanek S, Schiedner G. A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum Gene Ther 2002; 13: 1151-1156.
13. Morsy MA, Gu M, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998; 95: 7866-7871.
14. Wang L, Hernandez-Alcoceba R, Shankar V, et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology 2004; 126: 278-289.
15. Ng P, Parks R, Graham FL. Preparation of helper-dependent adenoviral vectors. In Methods in Molecular Medicine, Vol. 69, Gene Therapy Protocols, 2nd edn, Morgan JR (eds). Humana Press Inc.: Totowa, NJ; 2001.
16. Ng P, Parks RJ, Graham FL. Preparation of helper-dependent adenoviral vectors. Methods Mol Med 2002; 69: 371-388.
17. Palmer DJ, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther 2003; 8: 846-852.
18. Maizel JV, White DO, Scharff MD. The polypeptides of adenovirus. Evidence for multiple protein components in the virion and a comparison of types 2, 7A and 12. Virology 1968; 36: 115-125.
19. Sandig V, Youil R, Bett AJ, et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci USA 2000; 97: 1002-1007.
20. Crettaz J, Berraondo P, Mauleon I, et al. Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. Hepatology 2006; 44: 623-632.
21. Brunetti-Pierri N, Palmer DJ, Beaud AL, et al. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vector into nonhuman primates. Hum Gene Ther 2004; 15: 35-46.
22. Cerullo V, Seiler MP, Mane V, et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 2007; 15: 378-385.
23. Mane VP, Toietta G, McCormack WM, et al. Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors. Gene Ther 2006; 13: 1272-1280.
24. Muruve DA, Cotter MJ, Zaiss AK, et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 2004; 78: 5966-5972.
25. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.